SS Innovations Achieves Major Milestones with SSi Mantra Surgical Robotic System: Approvals for Telesurgery in Indonesia and the Philippines, 150+ Telesurgeries Completed

Key Highlights for Investors

• Regulatory Approvals: The SSi Mantra surgical robotic system has received landmark approvals for telesurgeries in both Indonesia and the Philippines, marking a significant expansion into new Southeast Asian markets.
• Demonstrated Medical Adoption: SS Innovations has surpassed 150 cumulative telesurgeries performed using the SSi Mantra system, with most procedures conducted in India—demonstrating robust real-world adoption and clinical validation.
• Showcase of Capabilities: Notably, on February 14, 2026, 18 inter-hospital telesurgeries were performed between two Indian cities within an eight-hour period, including 13 gastric bypass and 5 complex gynecological surgeries. This event highlights the system’s reliability, scalability, and versatility for different specialties.
• Technological Leadership: All surgeries leveraged the new SSi MantrAsana Tele Surgeon Console, a portable, self-contained console, which enables telesurgery from diverse environments, including physician offices.
• Scalability Proven: On December 23, 2025, nine surgeons performed 24 telesurgeries in a single 12-hour period—covering 10 different types of procedures, including intricate cardiac surgeries, across multiple Indian locations. This event further validates the system’s scalability and broad application potential.
• Upcoming Conference: SS Innovations will host the Global Multi-Specialty Robotic Surgery Conference 2026 (SMRSC 2026) in New Delhi, April 9-11, 2026, featuring 20+ live telesurgeries, positioning the company as a thought leader and innovator in the field. This event is expected to draw significant attention from medical professionals and industry stakeholders globally.

Why Shareholders Should Care

• Potential for Revenue Growth: The approval in Indonesia and the Philippines opens immediate access to large, untapped healthcare markets. These regulatory milestones can drive future sales and partnerships.
• Market Validation: Real-world telesurgery performance, especially in high-volume, high-complexity settings, provides strong evidence of product-market fit, which is critical for continued adoption and scaling.
• Competitive Positioning: The SSi Mantra’s portability, cost-effectiveness, and multi-specialty support distinguish it from more expensive, less flexible competitors. This could position SS Innovations as a disruptive force in the global surgical robotics industry.
• Ongoing Innovation: The company’s commitment to hosting high-profile conferences and enabling live demonstrations with global leaders may enhance its brand visibility and catalyze commercial opportunities.
• Expansion Strategy: With headquarters in India and a U.S. listing (Nasdaq: SSII), the company is ideally positioned to capture both emerging and developed market opportunities.
• Clinical Validation: More than 100 different types of surgical procedures have been successfully performed with the SSi Mantra in India, demonstrating versatility and safety across specialties—including cardiac surgery.

About the SSi Mantra System

The SSi Mantra system is a modular, multi-arm robotic platform with advanced features such as 3 to 5 robotic arms, an ergonomic open-faced surgeon command center, a 3D 4K monitor, touch panel interfaces, virtual real-time arm visualization, and superimposition of 3D diagnostic images. The vision cart ensures both the surgeon and the operative team have synchronized 4K 3D visuals, enhancing safety and efficiency. It is compatible with over 40 types of robotic endo-surgical instruments, supporting a wide range of specialties and procedures.

Looking Ahead

The company’s recent achievements and forthcoming initiatives indicate accelerating momentum, potentially translating into meaningful financial performance improvements. The expansion into new regulatory markets, continued clinical validation, and growing adoption rates are all positive signals for future revenue, competitive advantage, and shareholder value. The upcoming SMRSC 2026 conference is expected to further elevate SS Innovations’ profile and attract strategic interest.

Investor Relations and Media Contact

Investor Contact:
The Equity Group
Kalle Ahl, CFA: (303) 953-9878, [email protected]
Devin Sullivan, Managing Director: (212) 836-9608, [email protected]

Media Contact:
RooneyPartners LLC
Kate Barrette: (212) 223-0561, [email protected]

Disclaimer

This article contains forward-looking statements based on current expectations and projections about future events. Actual results may differ materially from those anticipated due to risks and uncertainties, including but not limited to competitive developments, regulatory changes, and market acceptance. Investors should conduct their own due diligence and consult with their financial advisors before making investment decisions. This article does not constitute investment advice or a recommendation to buy or sell securities.

View SS Innovations International, Inc. Historical chart here